In Novartis AG v. Torrent Pharmaceuticals Limited, [2016-1352] (April 12, 2017), the Federal Circuit affirmed the PTAB’s determination that the challenged claims of U.S. Patent No. 8,324,283, and Novaritis’ proposed substitute claims, were unpatentable as obvious. On appeal, Novaritis that it … Continue reading Just Because the Board Didn’t Say It; Doesn’t Mean that the Board Didn’t Think It